Rolling submission of Biologic License Application for teplizumab for the delay or prevention of clinical Type 1 diabetes in at-risk individuals initiated

Teplizumab is an anti-CD3 monoclonal antibody, proposed to inhibit autoimmune destruction of insulin-producing pancreatic beta cells. It is intended for use in at-risk individuals, as indicated by the presence of two or more type 1 diabetes-related autoantibodies.


Biospace Inc.